NanoBio's Decision To Go OTC With Its Cold Sore Med Pays Off With GSK Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately-held biotech chooses a different commercial path for its proprietary product and gains validation for its nano-emulsion delivery platform, NanoStat.
You may also be interested in...
GlaxoSmithKline Buys Back Into Dermatology With $2.9 Billion Stiefel Deal
Acquisition more than doubles GSK’s dermatology sales to $1.5 billion, creating a global specialist business across prescription and OTC drugs.
GSK Leverages Higher Return On OTC R&D Investment To Drive Growth – Witty
GlaxoSmithKline will be investing more R&D dollars in its consumer health care business, where spending on innovation pays off more quickly and more consistently than in the prescription sector, CEO Andrew Witty says
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.